Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fair is Fair; But Science is Science

This article was originally published in RPM Report

Executive Summary

Theravance’s proposed new indication for Vibativ is not the first drug to fail because of evolving regulatory standards. It may, however, have provoked the clearest and most formal articulation of FDA’s views on the limits of “fairness” regarding drug development commitments when it comes to approval decisions.

You may also be interested in...



Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN

FDA is sending a message to industry and Congress of its ongoing work to help companies with antibiotic drug development– beyond the requirements of the FDA Safety and Innovation Act.

“Feasibility” Counts at FDA: Different Approach in Antibiotics

Venture capitalists and other investors in drug development often howl about FDA policy changes that they view as crippling innovation in certain classes. They may not think FDA listens, but clearly the agency does. FDA just doesn’t always agree.

Data Integrity and Antibiotic Clinical Trials: FDA, Industry Try Systemic Therapy

FDA's push to encourage development of new antibiotics requires getting past data integrity issues in the class. The agency's workshop on antibacterial clinical trials revealed a range of efforts aimed at better Good Clinical Practices compliance - and those efforts can just as easily be applied to other drug classes

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS081046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel